Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV)


Morphology

  • SS negative-sense RNA virus
  • From the paramyxoviridae family
  • Enveloped nucleocapsid that encodes for 10 viral proteins
  • Matrix is made of M and M2 proteins

The viral envelope has two glycoproteins :

  1. G protein:
    • By which virus attaches to cell surface
  2.  F- protein ( Fusion protein:
    • which bring about the fusion between viral and host cell membranes. 
    • It is also responsible for cell to cell fusion, which leads to the characteristic syncytial formation.
Types

RSV can be subtyped into:

  • Type A
  • Type B

Types account for differences in:

  • The G protein composition
  • The conservation of the F protein in these 2 subtypes

Transmission:  

  • Direct contact with respiratory droplets such as sneezing or coughing
  • Close indirect contact with contaminated fomites such as used tissues
Clinical Manifestations:
  • RSV infection leads to a wide spectrum of respiratory illnesses. 

1. In infant cause:

  • pneumonia
  • bronchiolitis
  • tracheobronchitis.
  • In this age group, illness begins most frequently with rhinorrhea, low-grade fever, often accompanied by a cough and wheezing. 

2. In adults, the most common symptoms are:

  • a common cold, with rhinorrhea
  • sore throat
  • cough. 
  • It causes severe pneumonia in elderly. 

3. Sinusitis, otitis media, and worsening of chronic obstructive and reactive airway disease are also associated with RSV infection.

Diagnosis
For Bronchiolitis:
  • Chest X-ray shows:
  • Hyperinflation 
  • Multiple areas of interstitial infiltration

Bud tree Appearance:

  • MC cause of tree in bud (bronchiectasis) appearance is Mycobacterium tuberculosis (endobronchial).
  • Most common specific cause of tree in bud appearance in HSL (bone marrow) transplant patients is:
    • CMV (30-70%) > RSV (18%) > M. tuberculosis (5-6%) > Pneumocystis > Invasive aspergillosis.

Treatment

  • Oxygen: Mainstay of therapy.
  • Aerosolized ribavirin is used in the treatment of bronchiolitis with RSv

Prevention

Palivizumab:

  • Humanized monoclonal antibody
  • Directed against an epitope in the A antigen site on the F surface protein of RSV.
  • Licensed for the prevention of RSV infection in high-risk infants and children.
  • Once-monthly intramuscular injections (15 mg/kg) for 5 months beginning at the start of the RSV season

Exam Important

 Morphology

  • SS negative-sense RNA virus
  • The viral envelope has two glycoproteins :
  1. G protein:
    • By which virus attaches to cell surface
  2.  F- protein ( Fusion protein:
    • which bring about the fusion between viral and host cell membranes. 
Types
  • RSV can be subtyped into:
    •  Type A
    • Type B

Clinical Manifestations:

  • RSV infection leads to a wide spectrum of respiratory illnesses. 

1. In infant cause:

  • pneumonia
  • bronchiolitis
  • tracheobronchitis.
  • In this age group, illness begins most frequently with rhinorrhea, low-grade fever, often accompanied by a cough and wheezing. 

2. In adults, the most common symptoms are:

  • a common cold, with rhinorrhea
  • sore throat
  • cough. 
  • It causes severe pneumonia in elderly. 

3. Sinusitis, otitis media, and worsening of chronic obstructive and reactive airway disease are also associated with RSV infection.Diagnosis

For Bronchiolitis:
  • Chest X-ray shows:
  • Hyperinflation 
  • Multiple areas of interstitial infiltration

Bud tree Appearance:

  • MC cause of tree in bud (bronchiectasis) appearance is Mycobacterium tuberculosis (endobronchial).
  • Most common specific cause of tree in bud appearance in HSL (bone marrow) transplant patients is:
    • CMV (30-70%) > RSV (18%) > M. tuberculosis (5-6%) > Pneumocystis > Invasive aspergillosis.

Treatment

  • Oxygen: Mainstay of therapy.
  • Aerosolized ribavirin is used in the treatment of bronchiolitis with RSv

Prevention

Palivizumab:

  • Humanized monoclonal antibody
  • Directed against an epitope in the A antigen site on the F surface protein of RSV.
  •  Licensed for the prevention of RSV infection in high-risk infants and children.
  • Once-monthly intramuscular injections (15 mg/kg) for 5 months beginning at the start of the RSV season
Don’t Forget to Solve all the previous Year Question asked on Respiratory Syncytial Virus (RSV)
Click Here to Start Quiz

Module Below Start Quiz

Leave a Reply

Discover more from New

Subscribe now to keep reading and get access to the full archive.

Continue reading

👨‍⚕️
Chat Support